Odyssey Health, Inc.: 10-Q filed 2021-06-21
What Odyssey Health, Inc. reported in its quarterly report filed 2021-06-21 (fiscal Q3 2021): 24 published measures, 70 facts as tagged in accession 0001683168-21-002648.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-06-21
- Fiscal period
- fiscal Q3 2021
- Accession
- 0001683168-21-002648 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Odyssey Health, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 1,453,777 | USD | |
| At 2020-07-31 | 105,584 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 2,400,688 | USD | |
| At 2020-07-31 | 757,063 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | -946,911 | USD | |
| At 2021-01-31 | -1,015,971 | USD | |
| At 2020-10-31 | -549,979 | USD | |
| At 2020-07-31 | -651,479 | USD | |
| At 2020-04-30 | -1,228,266 | USD | |
| At 2020-01-31 | -1,025,699 | USD | |
| At 2019-10-31 | -876,628 | USD | |
| At 2019-07-31 | -593,758 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 1,378,225 | USD | |
| At 2020-07-31 | 62,952 | USD | |
| At 2020-04-30 | 26,642 | USD | |
| At 2019-07-31 | 167,095 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | -12,401,690 | USD | 89 |
| 2020-08-01 to 2021-04-30 | -13,982,504 | USD | 273 |
| 2020-02-01 to 2020-04-30 | -999,275 | USD | 90 |
| 2019-08-01 to 2020-04-30 | -3,016,832 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-08-01 to 2021-04-30 | -2,461,232 | USD | 273 |
| 2019-08-01 to 2020-04-30 | -340,453 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-08-01 to 2021-04-30 | 3,776,505 | USD | 273 |
| 2019-08-01 to 2020-04-30 | 200,000 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-08-01 to 2021-04-30 | 0 | USD | 273 |
| 2019-08-01 to 2020-04-30 | 0 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | -42,833,232 | USD | |
| At 2020-07-31 | -28,850,728 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 552 | USD | |
| At 2020-07-31 | 965 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-08-01 to 2021-04-30 | 1,129,446 | USD | 273 |
| 2019-08-01 to 2020-04-30 | 2,046,895 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | -12,094,320 | USD | 89 |
| 2020-08-01 to 2021-04-30 | -13,253,380 | USD | 273 |
| 2020-02-01 to 2020-04-30 | -867,665 | USD | 90 |
| 2019-08-01 to 2020-04-30 | -2,690,140 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 1,453,225 | USD | |
| At 2020-07-31 | 99,619 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 357,370 | USD | 89 |
| 2020-08-01 to 2021-04-30 | 779,124 | USD | 273 |
| 2020-02-01 to 2020-04-30 | 131,610 | USD | 90 |
| 2019-08-01 to 2020-04-30 | 326,692 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 2,400,688 | USD | |
| At 2020-07-31 | 707,063 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 338,845 | USD | |
| At 2020-07-31 | 269,388 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 0 | USD | |
| At 2020-07-31 | 5,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 565,764 | USD | 89 |
| 2020-08-01 to 2021-04-30 | 608,383 | USD | 273 |
| 2020-02-01 to 2020-04-30 | 0 | USD | 90 |
| 2019-08-01 to 2020-04-30 | 10,000 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 101,539,105 | shares | |
| At 2020-07-31 | 88,559,978 | shares |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-04-30 | 2,758 | USD | |
| At 2020-07-31 | 2,345 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | -12,401,690 | USD | 89 |
| 2020-11-01 to 2021-01-31 | -869,300 | USD | 92 |
| 2020-08-01 to 2020-10-31 | -711,514 | USD | 92 |
| 2020-02-01 to 2020-04-30 | -999,275 | USD | 90 |
| 2019-11-01 to 2020-01-31 | -600,945 | USD | 92 |
| 2019-08-01 to 2019-10-31 | -1,416,612 | USD | 92 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-02-01 to 2021-04-30 | 2,654,320 | USD | 89 |
| 2020-08-01 to 2021-04-30 | 3,813,380 | USD | 273 |
| 2020-02-01 to 2020-04-30 | 867,665 | USD | 90 |
| 2019-08-01 to 2020-04-30 | 2,690,140 | USD | 274 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-08-01 to 2021-04-30 | 30,310 | USD | 273 |
| 2019-08-01 to 2020-04-30 | 0 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-08-01 to 2021-04-30 | 69,457 | USD | 273 |
| 2019-08-01 to 2020-04-30 | 17,173 | USD | 274 |
Inspect the source
- Entity
- Odyssey Health, Inc. / CIK 0001626644
- Captured
- 2026-09-19T11:19:48.570Z
- SEC response SHA-256
1be33e1ca79fd1e1d5399b519a2ef141b4c1191380216b92c135e07a22902f7b
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001626644.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))